RealTeaNewsAI, Tech & CryptoExplainer

Inside the FDA file: what regulators actually wrote about Neuralink

Part A only. This piece restates documented FDA friction, inspection findings and congressional correspondence as reported by named outlets. It does not treat any "torture cover-up" claim as fact. Nobody was contacted.

Published

AI-generated illustration: stylised regulator document with blurred text and a magnifying glass – not an official form.
AI-generated image. Illustrative blurred regulator-style page with magnifying glass; no logos, no patients. AI-generated illustration for RealTeaNews.

Before Neuralink became a culture-war magnet, it was a medical-device file. Reuters investigations, FDA inspection material obtained via Redica Systems, and a November 2024 FDA letter to Congress summarised for the public what regulators actually flagged: earlier rejection of a human-study bid, dozens of deficiencies including battery and wire-migration concerns, June 2023 animal-lab quality and record-keeping problems in California, and later wording that those conditions were “objectionable” yet steered toward voluntary remediation rather than harder action on the device path. That is the paper trail. RTN will stay inside it for this Day 3 explainer – Part A of the Neuralink thread – and leave Part B allegations for pieces that can still show an evidence gap.

What “the FDA file” means in public

RTN does not have Neuralink’s full confidential IND/IDE correspondence. What exists in open reporting is:

  1. Staff-sourced accounts of an early-2022 rejection of Neuralink’s bid to start human testing, with “dozens” of deficiencies.
  2. June 2023 FDA inspection findings at the California animal site (and a contrasting Texas visit), reported by Reuters from material obtained through Redica Systems.
  3. A 29 November 2024 FDA letter to Rep. Earl Blumenauer, described by Reuters on 5 December 2024, using the phrase “objectionable conditions or practices” and framing remediation as voluntary.

Those layers are not the same document. Collapsing them into “the FDA said Neuralink is unsafe forever” or “the FDA cleared everything” both overstate the file.

Layer 1 – The earlier human-study rejection

A Reuters special report, based on current and former Neuralink employees, said the company sought FDA permission in early 2022 and was rejected. Staff who had seen the agency’s explanation told Reuters the major safety themes included:

  • the implant’s lithium battery and failure risk (including heat/electrical harm to tissue);
  • possible migration of hair-thin electrode wires into other brain areas;
  • questions about explant / removal without damaging brain tissue.

Reuters framed that rejection as previously unreported at the time of the special report. Neuralink later said it had clearance for a small early-feasibility human study – a narrow path, not a broad licence to sell implants. RTN repeats that distinction: early-feasibility clearance is not commercial approval.

Layer 2 – June 2023 animal-lab inspection

Reuters later reported FDA inspection material from June 2023 visits. Inspectors flagged quality-control and record-keeping problems at the California animal research site – examples in the coverage included missing calibration records for instruments used in animal tests, and incomplete quality-assurance sign-off on study reports and protocol deviations. A Texas visit, in that reporting, did not draw the same findings.

Timing mattered politically: Blumenauer and others asked how inspection findings lined up against the human-study clearance Neuralink had announced. That is a oversight question. It is still not a finding that human participants were tortured.

Layer 3 – “Objectionable conditions” letter to Congress

On 5 December 2024 Reuters reported that in a 29 November letter to Blumenauer the FDA said the California lab had “objectionable conditions or practices,” urged the company to address them, and judged the issues not severe enough for harder regulatory action on the device path as described in that coverage. An FDA statement quoted by Reuters said citations related to documentation of animal research, and that the inspection did not find evidence of violations that would undermine the device’s safety.

Read that twice. “Objectionable” is real regulator language in the letter as reported. “Undermine the device’s safety” is the agency’s public framing that documentation problems were not treated as a kill-switch for the human study. Critics (including Blumenauer’s prior letters) disputed the timing and seriousness; Neuralink has disputed cruelty characterisations in parallel animal-welfare fights. RTN reports the tension; it does not pick a courtroom winner.

What sits beside the FDA file – and what this article will not do

PCRM litigation over UC Davis monkey records, USDA correspondence, employee “hack jobs” accounts in Reuters’ December 2022 animal-testing probe, and early human-participant thread-retraction reporting are related controversies. Day 6 of this series is reserved for the animal-testing claims stack. Day 3 stays on what regulators wrote / what wires reported regulators wrote.

Out of scope for this Part A piece: any claim that Neuralink exists to hide torture of people via implants. That remains an allegation with an evidence gap (see RTN-0062 Part B). Stating it as fact would be false to the public file opened for this draft.

What we do not know

  • The full unpublished deficiency list from the early-2022 rejection, beyond what staff described to Reuters.
  • Whether every June 2023 observation matches the later “objectionable conditions” phrasing one-for-one (FDA declined some detail in Reuters’ questions).
  • Future inspection outcomes, warning letters, or clinical holds not yet public.
  • Clinical results for every human participant beyond company statements and major wire reporting.

Sources

  1. U.S. regulators rejected Elon Musk’s bid to test brain chips in humans – Reuters special report – accessed 6 Nov 2026 (early-2022 rejection; battery, wire migration, explant concerns; staff accounts)
  2. Musk’s Neuralink brain implant company cited by FDA over animal lab issues – Reuters, 29 Feb 2024 – accessed 6 Nov 2026 (June 2023 inspection; California vs Texas; Redica Systems material)
  3. US FDA cited animal lab at Musk’s Neuralink for ‘objectionable conditions’ – Reuters, 5 Dec 2024 – accessed 6 Nov 2026 (29 Nov letter to Blumenauer; voluntary remediation; FDA safety framing)
  4. Exclusive: US lawmaker seeks answers on FDA inspection of Musk’s Neuralink – Reuters, 26 Mar 2024 – accessed 6 Nov 2026 (Blumenauer questions on inspection timing vs human clearance)
  5. Physicians Group Asks FDA to Investigate Elon Musk’s Neuralink… – Physicians Committee for Responsible Medicine – accessed 6 Nov 2026 (adjacent animal-records advocacy; not treated as FDA text)
  6. Not relied on as FDA findings: anonymous forum posts, unverified implant photos, or any “torture cover-up” narrative stated as fact. Nobody was contacted.

Disclosure

Disclosure: RealTeaNews uses Grok Bot to help research its articles. SpaceX owns xAI, which makes Grok, and X; Neuralink is also an Elon Musk company. This article was reviewed by our editor.

Sources

  1. U.S. regulators rejected Elon Musk's bid to test brain chips in humans, Reuters special report. Accessed 6 November 2026.
  2. Musk's Neuralink brain implant company cited by FDA over animal lab issues, Reuters, 29 Feb 2024. Accessed 6 November 2026.
  3. US FDA cited animal lab at Musk's Neuralink for 'objectionable conditions', Reuters, 5 Dec 2024. Accessed 6 November 2026.
  4. Exclusive: US lawmaker seeks answers on FDA inspection of Musk's Neuralink, Reuters, 26 Mar 2024. Accessed 6 November 2026.
  5. Physicians Group Asks FDA to Investigate Elon Musk's Neuralink…, Physicians Committee for Responsible Medicine. Accessed 6 November 2026.

Sources link to external sites. Their content is the responsibility of their publishers.

More in AI, Tech & Crypto